Cetuximab (Erbitux®; Imclone Systems Inc./Bristol-Myers Squibb) and panitumumab (Vectibix®; Amgen Inc.)are anti–epidermal growth factor receptor (EGFR) monoclonal antibodies that may be used for first-, second- or third-line treatment in patients with metastatic disease[7], [8], [9]. Here, EGFR is linked to metastatic neoplasm.